Coleman-Minahan K, Ela EJ, White K, et al. - Utilizing data from the Texas Postpartum Contraception Study (2014–2018), researchers sought to investigate the prevalence of contraindications to hormonal contraception among postpartum women. Low-income postpartum women who planned to delay childbearing for 2 years or longer after delivery were selected for a prospective cohort study from eight Texas hospitals. Of the 1,452 women who completed the 6-month interview, 19.1% had a category 3 or 4 contraindication to combined hormonal contraception (16.8% category 4) and 5.4% had a contraindication to depot medroxyprogesterone acetate (0.1% category 4). Almost one in every five participants had a category 3 or 4 contraindication to combined hormonal contraception. Contraindications are more likely in patients who are at a higher risk of adverse birth outcomes. Physicians should advise on contraception and contraindications prenatally to facilitate the most informed postpartum decision.